ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE)

BRIEF

published on 12/09/2025 at 07:35, 9 days 4 hours ago

OSE Immunotherapeutics annonce son plan stratégique pour 2026-2028

Plan Stratégique Stratégie Financière Leadership Scientifique Essai Tedopi Développement Du Lusvertikimab
BRIEF

published on 12/09/2025 at 07:35, 9 days 4 hours ago

OSE Immunotherapeutics' new strategic plan for 2026-2028

Strategic Plan Funding OSE Immunotherapeutics Lusvertikimab Tedopi® Phase 3
BRIEF

published on 12/09/2025 at 07:35, 9 days 4 hours ago

OSE Immunotherapeutics Announces Strategic Plan for 2026–2028

Strategic Plan Financial Strategy Scientific Leadership Tedopi Trial Lusvertikimab Development
BRIEF

published on 12/09/2025 at 07:35, 9 days 4 hours ago

Nouveau plan stratégique d'OSE Immunotherapeutics pour 2026-2028

Financement Plan Stratégique OSE Immunotherapeutics Lusvertikimab Tedopi® Phase 3
PRESS RELEASE

published on 12/09/2025 at 07:30, 9 days 4 hours ago

OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation
OSE Immunotherapeutics unveils 2026–2028 strategic plan focusing on Tedopi's phase 3, rare indications for Lusvertikimab, subcutaneous formulation in UC, and maintaining scientific leadership

Strategic Plan Scientific Leadership OSE Immunotherapeutics Tedopi Phase 3 Lusvertikimab Indications
PRESS RELEASE

published on 12/09/2025 at 07:30, 9 days 4 hours ago

OSE Immunotherapeutics dévoile son plan stratégique 2026 - 2028 axé sur quatre leviers de création de valeur
OSE Immunotherapeutics dévoile un plan stratégique 2026-2028 axé sur la phase 3 de Tedopi®, Lusvertikimab, et la RCH, renforçant l'engagement en immunologie

Plan Stratégique Valeur OSE Immunotherapeutics Immunologie Catalyseurs
PRESS RELEASE

published on 10/16/2025 at 19:58, 2 months 1 day ago

RAPPORT FINANCIER SEMESTRIEL 2025
BRIEF

published on 10/15/2025 at 19:05, 2 months 2 days ago

OSE Immunotherapeutics publie ses résultats financiers du premier semestre 2025

Baisse Des Revenus OSE Immunotherapeutics Dépenses De R&D Piste De Trésorerie Résultats Financiers 2025
BRIEF

published on 10/15/2025 at 19:05, 2 months 2 days ago

OSE Immunotherapeutics Reports 2025 First Half Financial Results

Revenue Decline OSE Immunotherapeutics Cash Runway R&D Expenses 2025 Financial Results
PRESS RELEASE

published on 10/15/2025 at 19:00, 2 months 2 days ago

OSE Immunotherapeutics Reports First Half 2025 Financial Results
OSE Immunotherapeutics reports first half 2025 financial results with operating loss of 15.8 million euros and net loss of 15.1 million euros. Research and development expenses increased 6.7%

Financial Results Net Loss Operating Loss OSE Immunotherapeutics Research And Development Expenses

1 2 ... 9

Published on 12/18/2025 at 06:25, 5 hours 18 minutes ago

1933 Industries Announces Maturity of Unsecured Convertible Debentures and Encourages Conversion to Support Continued Growth
Published on 12/18/2025 at 00:55, 10 hours 48 minutes ago

Molten Metals Corp. Announces Flow-Through Financing
Published on 12/18/2025 at 00:00, 11 hours 43 minutes ago

Right Season Investments Announces Name Change to FutureGen Industries Corp.
Published on 12/17/2025 at 23:15, 12 hours 28 minutes ago

Northern Superior Announces the Ratio for the Distribution of the Common Shares in the Capital of ONGold Resources Ltd.
Published on 12/17/2025 at 15:00, 20 hours 43 minutes ago

BlackBerry Unveils Ground-Up Modernization of BlackBerry AtHoc Mobile Experience to Enable More Intelligent Operations

View all ACCESSWIRE

Published on 12/18/2025 at 11:33, 10 minutes ago

Notification pursuant to Article 5 para. 1 lit b), para. 3 of the Regulation (EU) No 596/2014 (MAR) Acquisition of own shares - final notice
Published on 12/18/2025 at 11:30, 13 minutes ago

A Global Playground: Haier's 2026 Global Fans Festival Champions Sports, Tech, and Community
Published on 12/18/2025 at 11:00, 43 minutes ago

ABB Ltd: ABB share buybacks - December 11, 2025 - December 17, 2025
Published on 12/18/2025 at 11:00, 43 minutes ago

BIRKENSTOCK REPORTS FISCAL 2025 REVENUE GROWTH AHEAD OF TARGET, OUTPERFORMING ADJUSTED EBITDA AND EARNINGS GROWTH; SETS FISCAL 2026 TARGETS
Published on 12/18/2025 at 10:47, 56 minutes ago

Blue Cap AG with broadened investor base: Major shareholder PartnerFonds AG i.L. publishes results of share exchange offer

View all EQS

Published on 12/18/2025 at 10:00, 1 hour 43 minutes ago

Neoen remporte 124 MWc de projets solaires en France
Published on 12/17/2025 at 20:39, 15 hours 4 minutes ago

Aeroports de Paris SA | 2026 Airport charges in Paris
Published on 12/17/2025 at 20:39, 15 hours 4 minutes ago

Aeroports de Paris SA | Tarifs des redevances aeroportuaires 2026 à Paris
Published on 12/17/2025 at 19:30, 16 hours 13 minutes ago

Change in the composition of the Board
Published on 12/17/2025 at 19:30, 16 hours 13 minutes ago

Evolution de la composition du Conseil d’Administration

View all LES ECHOS COMFI WIRE

News